In patients with chronic metabolic diseases, such as type 2 diabetes patients with hyperlipidemia or dyslipidemia, or patients with hepatic fibrosis and atherosclerosis, it can be recommended that dual targeting of NOX and NOS be actively considered to restore redox homeostasis in addition to the treatment of metabolic diseases [[328], [329], [330]]. The gene discussed is NOS1; the disease is type 2 diabetes mellitus.